[登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > Tirofiban hydrochloride monohydrate
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Tirofiban hydrochloride monohydrate
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
Tirofiban hydrochloride monohydrate图片
CAS NO:150915-40-5
包装与价格：
包装价格(元)
10mM (in 1mL DMSO)电议
5mg电议
25mg电议

产品介绍
Tirofiban (L700462) hydrochloride monohydrate 是一种选择性和可逆的血小板整合素受体 (Gp IIb/IIIa) 拮抗剂，可抑制纤维蛋白原与该受体的结合并具有抗血栓形成活性。
Cas No.150915-40-5
别名盐酸替罗非班水合物; L700462 hydrochloride monohydrate; MK383 hydrochloride monohydrate
化学名(S)-2-(butylsulfonamido)-3-(4-(4-(piperidin-4-yl)butoxy)phenyl)propanoic acid hydrochloride hydrate
Canonical SMILESO=C(O)[C@@H](NS(=O)(CCCC)=O)CC1=CC=C(OCCCCC2CCNCC2)C=C1.Cl.O
分子式C22H39ClN2O6S
分子量495.07
溶解度≥ 24.75 mg/mL in DMSO, ≥ 105 mg/mL in EtOH with ultrasonic, ≥ 3.84 mg/mL in Water with ultrasonic and warming
储存条件Store at RT
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Tirofiban hydrochloride monohydrate is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonistIC50 value:Target: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation. Tirofiban is an antithrombotic used in the treatment of unstable angina.Tirofiban, in a concentration-dependent manner reduced platelet aggregation evoked by ADP (IC50 approximately 70 ng/ml), collagen (IC50 approximately 200 ng/ml), and thrombin (IC50 approximately 5,000 ng/ml).

References:
[1]. Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):138-46.
[2]. van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100.
[3]. Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49.
[4]. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19.
[5]. Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53.